These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38134560)

  • 1. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
    Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
    Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
    Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
    Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
    JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
    Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
    Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
    Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
    J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie RC; Yuan SQ; Wang Y; Zou XB; Chen S; Li SM; Duan JL; Zhou J; Chen GM; Luo TQ; Zhou ZW; Li YF
    Ther Adv Med Oncol; 2020; 12():1758835920929583. PubMed ID: 32595775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.
    Kabir ER; Azam F; Khan TTS; Yasmin H; Chowdhury NM; Ahmed SM; Sagar BH; Tahrim NA
    Cancer Med; 2024 Oct; 13(19):e70289. PubMed ID: 39387320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of surrogate endpoints for predicting real-world survival across five cancer types.
    Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
    Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
    Veas Rodríguez J; Prieto A; Vilaprinyo E; Bonet M; Diez M; Salud A; Montal R
    Crit Rev Oncol Hematol; 2024 Sep; 201():104416. PubMed ID: 38871262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.